For the year ending 2025-12-31, COYA had $8,483,024 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Collaboration revenue | 7,945,753 |
| Total research and development expenses | 16,734,549 |
| In-process research and development | 2,289,602 |
| Total general and administrative expenses | 11,449,466 |
| Depreciation | 27,361 |
| Other income | 1,332,207 |
| Pre-tax loss | -21,223,018 |
| Income tax benefit | 3,089 |
| Net loss | -21,226,107 |
| Depreciation | 27,361 |
| Stock-based compensation, including the issuance of restricted stock | 4,290,315 |
| Acquired in-process research and development | 2,289,602 |
| Prepaids and other current assets | -2,852,434 |
| Accounts payable | -527,006 |
| Accrued expenses | 1,099,853 |
| Deferred collaboration revenue | 454,247 |
| Net cash used in operating activities | -10,739,301 |
| Purchase of in-process research and development assets | 1,164,602 |
| Net cash used in investing activities | -1,164,602 |
| Proceeds from sale of common stock, net of offering costs | 20,348,653 |
| Proceeds from the exercise of stock options | 38,274 |
| Net cash provided by financing activities | 20,386,927 |
| Net increase in cash and cash equivalents | 8,483,024 |
| Cash and cash equivalents as of beginning of the year | 38,339,762 |
| Cash and cash equivalents as of end of the year | 46,822,786 |
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)